Using RWE to Make Cost Decisions: A New Report
A recent article, published in JMCP (the Journal of Managed Care and Specialty Pharmacy), considers how RWE (real world… Read more
HEOR Feature
Featured
Biogen Controversy Highlights FDA’s Rules Surrounding Expert Panels
The Food and Drug Administration (FDA)’s approval of Biogen’s Aduhelm was based on shaky data. The resulting controversy continues to build and shed… Read more
Surface Ophthalmics Announces $25 Million Private Round of Fundraising
Surface Ophthalmics Announces $25 Million Private Round of Fundraising |[21-July-2021]| Proceeds from the capital raise will help to support and… Read more
Unforgivable Hypocrisy From FDAs Career CDER Leadership
The FDA leadership team’s hesitancy on Trump’s nCoV-2019 vaccines and hydroxychloroquine somehow didn’t apply to Biogen’s Aduhelm (aducanumab) review.… Read more
The Latest Blogs from tHEORetically Speaking
- Generating evidence for optimal market access – an Executive Interview with Jeff Anderson and Rosemary Jose, OPEN Health
- All About the Value, Evidence and Access Marketplace: Interview with Scientist.com Category Experts
- Education Spotlight – Xavier Health Economics & Clinical Outcomes Research
- Supplier Spotlight – Self Care Catalysts
- Getting the most from clinical experts in the time of COVID-19: Lessons learned
